ClinicalTrials.gg
CompletedNCT00389831Updated Oct 2, 2014Results posted

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

A Phase 2 interventional study of Rotigotine Nasal Spray and Placebo Nasal Spray in Restless Legs Syndrome, sponsored by UCB Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
13th of 19
44 · median 130
Started
2006
with 1 other
Phase 2
6 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
8 of 19
UCB Pharma

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 2, and was the 5th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The main objective of this phase 2a proof-of-concept trial is to assess the efficacy of rotigotine nasal spray in ascending doses in subjects with idiopathic Restless Legs Syndrome.

Read the detailed description

Each patient of the placebo and rotigotine group performed an Eligibility Assessment, as well 4 treatment days at which subjects performed a repeated 'Suggested Immobilization Test' (SIT) during a 30min pre-dose and a 4 hours post-dose period. During these periods the severity of RLS symptoms in the legs was assessed by the subject using a numeric symptom severity scale.

In addition the leg movements were measured by actigraphy to assess the Periodic Leg Movement Index during Wakefulness (PLMWI, PLM per hour). Subjects applied a single dose of treatment on each treatment day (placebo nasal spray or rotigotine nasal spray in 3 ascending doses).

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • Rotigotine
  • Rotigotine nasal spray
  • Efficacy, safety and tolerability
  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with idiopathic RLS, who are responding to an ongoing L-dopa treatment

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary RLS or concomitant diseases or medical conditions are excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects receiving a single dose of placebo nasal spray on all 4 treatment days

    Other: Placebo Nasal Spray

  • Experimental
    Rotigotine Nasal Spray

    Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4

    Drug: Rotigotine Nasal Spray

Interventions

  • Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution

    Also known as: SPM937

  • OtherPlacebo Nasal Spray

    Daily single dose of placebo delivered as single puff of nasal spray solution

06

What researchers measure

Primary outcomes

  1. Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo

    Subjects rate the severity of the RLS symptoms at the start of each pre dose and post dose Suggested Immobilization Test (SIT-0 to SIT-6) and every 5min during each SIT, using a numeric symptoms severity scale, where 0=not severe and 10=very severe.

    Time frame: 4 hours post-treatment period at each treatment day

  2. Average PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo.

    The Periodic Limb Movement (PLM) during Wakefulness Index (PLMWI) measures the number of limb movements per hour and indicates the frequency of PLMs when the subject is awake and the degree of motor symptoms of the disorder during wake time. No movements would result in a score of 0 PLM per hour. Outcome is the average movements per hour in the 4 hour post-dose period per subject.

    Time frame: 4 hours post-treatment period at each treatment day

07

Results

Posted Sep 4, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboRotigotine Nasal Spray
Started1034
Completed1027
Not completed07
Withdrew: Lack of efficacy02
Withdrew: Did not receive treatment.02
Withdrew: Other reasons02
Withdrew: Lost to follow-up01

Outcome measures

PrimaryAverage Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo

Subjects rate the severity of the RLS symptoms at the start of each pre dose and post dose Suggested Immobilization Test (SIT-0 to SIT-6) and every 5min during each SIT, using a numeric symptoms severity scale, where 0=not severe and 10=very severe.

Time frame:
4 hours post-treatment period at each treatment day
Reported as:
Mean · score on a scale
Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo
score on a scalePlacebo - Day 1Placebo - Day 2Placebo - Day 3Placebo - Day 4Rotigotine Nasal Spray - PlaceboRotigotine Nasal Spray - Rotigotine 62µgRotigotine Nasal Spray - Rotigotine 124µgRotigotine Nasal Spray - Rotigotine 247µg
Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo2.6 ± 1.762.2 ± 1.442.5 ± 2.032.0 ± 1.652.9 ± 1.992.7 ± 1.842.0 ± 1.141.5 ± 1.21
PrimaryAverage PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo.

The Periodic Limb Movement (PLM) during Wakefulness Index (PLMWI) measures the number of limb movements per hour and indicates the frequency of PLMs when the subject is awake and the degree of motor symptoms of the disorder during wake time. No movements would result in a score of 0 PLM per hour. Outcome is the average movements per hour in the 4 hour post-dose period per subject.

Time frame:
4 hours post-treatment period at each treatment day
Reported as:
Mean · PLM per hour
Average PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo.
PLM per hourPlacebo - Day 1Placebo - Day 2Placebo - Day 3Placebo - Day 4Rotigotine Nasal Spray - PlaceboRotigotine Nasal Spray - Rotigotine 62µgRotigotine Nasal Spray - Rotigotine 124µgRotigotine Nasal Spray - Rotigotine 247µg
Average PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo.37.8 ± 35.1022.6 ± 28.3634.9 ± 39.7819.0 ± 23.6028.7 ± 29.9125.4 ± 25.1426.2 ± 22.7820.2 ± 21.70

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Day 1—0/10 (0%)4/10 (40%)
Placebo - Day 2—0/10 (0%)3/10 (30%)
Placebo - Day 3—0/10 (0%)2/10 (20%)
Placebo - Day 4—0/10 (0%)2/10 (20%)
Rotigotine Nasal Spray - Placebo—0/31 (0%)16/31 (51.6%)
Rotigotine Nasal Spray - Rotigotine 62µg—0/31 (0%)14/31 (45.2%)
Rotigotine Nasal Spray - Rotigotine 124µg—0/28 (0%)10/28 (35.7%)
Rotigotine Nasal Spray - Rotigotine 247µg—0/28 (0%)11/28 (39.3%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPlacebo - Day 1Placebo - Day 2Placebo - Day 3Placebo - Day 4Rotigotine Nasal Spray - PlaceboRotigotine Nasal Spray - Rotigotine 62µgRotigotine Nasal Spray - Rotigotine 124µgRotigotine Nasal Spray - Rotigotine 247µg
HeadacheNervous system disorders3/102/100/102/109/315/313/283/28
PalpitationsCardiac disorders0/101/100/100/100/310/311/280/28
Eye irritationEye disorders0/100/101/100/100/310/311/280/28
DiarrhoeaGastrointestinal disorders1/100/100/101/102/310/310/280/28
Abdominal painGastrointestinal disorders0/100/100/101/100/310/310/280/28
FatigueGeneral disorders1/100/100/100/101/311/311/280/28
Neck painMusculoskeletal and connective tissue disorders0/101/100/100/100/310/310/280/28
ParaesthesiaNervous system disorders0/100/101/100/100/310/310/280/28
Nasal congestionRespiratory, thoracic and mediastinal disorders0/100/101/100/101/310/310/280/28
SneezingRespiratory, thoracic and mediastinal disorders0/100/101/100/100/310/310/280/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboRotigotine Nasal SprayTotal
<=18 years000
Between 18 and 65 years93342
>=65 years112
Age, Continuous
Age, Continuous(years)PlaceboRotigotine Nasal SprayTotal
Mean55.5 ± 5.4052.9 ± 7.7853.5 ± 7.33
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotine Nasal SprayTotal
Female82129
Male21315
Region of Enrollment
Region of Enrollment(participants)PlaceboRotigotine Nasal SprayTotal
Germany103444
08

Study locations

1 site
  • Schwarz BioSciences GmbH
    Monheim, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Nov 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2006
First posted
Oct 19, 2006
Start
Aug 2006
Primary completionActual
Nov 2006
CompletionActual
Dec 2006
Results first posted
Sep 4, 2009
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00389831
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Oct 19, 2006
Start date
Aug 2006
Primary completion
Nov 2006
Completion
Dec 2006
Results posted
Sep 4, 2009
Last update
Oct 2, 2014

Study contacts

Marianne Raetz
study director · Schwarz BioSciences GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion